133 related articles for article (PubMed ID: 9195297)
1. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.
Kitamura Y; Kohno Y; Nakazawa M; Nomura Y
Jpn J Pharmacol; 1997 May; 74(1):51-7. PubMed ID: 9195297
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
[TBL] [Abstract][Full Text] [Related]
3. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.
Kitamura Y; Kosaka T; Kakimura JI; Matsuoka Y; Kohno Y; Nomura Y; Taniguchi T
Mol Pharmacol; 1998 Dec; 54(6):1046-54. PubMed ID: 9855633
[TBL] [Abstract][Full Text] [Related]
5. Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets.
Irifune M; Nomoto M; Fukuda T
Eur J Pharmacol; 1993 Jul; 238(2-3):235-40. PubMed ID: 8104807
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model.
Kitamura Y; Kakimura J; Taniguchi T
Jpn J Pharmacol; 1998 Sep; 78(1):23-9. PubMed ID: 9804058
[TBL] [Abstract][Full Text] [Related]
7. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
Domino EF; Ni L; Zhang H; Kohno Y; Sasa M
Eur J Pharmacol; 1997 May; 325(2-3):137-44. PubMed ID: 9163560
[TBL] [Abstract][Full Text] [Related]
8. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter.
Clarke PB; Reuben M
Br J Pharmacol; 1995 Jan; 114(2):315-22. PubMed ID: 7881731
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice.
Zou L; Xu J; Jankovic J; He Y; Appel SH; Le W
Neurosci Lett; 2000 Mar; 281(2-3):167-70. PubMed ID: 10704769
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo.
Carter AJ; Müller RE
Eur J Pharmacol; 1991 Jul; 200(1):65-72. PubMed ID: 1685123
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.
Anderson DW; Neavin T; Smith JA; Schneider JS
Brain Res; 2001 Jun; 905(1-2):44-53. PubMed ID: 11423078
[TBL] [Abstract][Full Text] [Related]
12. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
Irifune M; Nomoto M; Fukuda T
Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
[TBL] [Abstract][Full Text] [Related]
13. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
[TBL] [Abstract][Full Text] [Related]
14. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Yabe H; Choudhury ME; Kubo M; Nishikawa N; Nagai M; Nomoto M
J Pharmacol Sci; 2009 May; 110(1):64-8. PubMed ID: 19403994
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice.
Selley ML
Brain Res; 2005 Mar; 1037(1-2):1-6. PubMed ID: 15777746
[TBL] [Abstract][Full Text] [Related]
16. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice.
Tabatabaei A; Perry TL; Hansen S; Krieger C
Neurosci Lett; 1992 Jul; 141(2):192-4. PubMed ID: 1436633
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of riluzole in MPTP-treated mice.
Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Mierau J; Schingnitz G
Eur J Pharmacol; 1992 May; 215(2-3):161-70. PubMed ID: 1356788
[TBL] [Abstract][Full Text] [Related]
19. A new in vitro approach for investigating the MPTP effect on DA uptake.
Barc S; Page G; Fauconneau B; Barrier L; Huguet F
Neurochem Int; 2001 Mar; 38(3):243-8. PubMed ID: 11099783
[TBL] [Abstract][Full Text] [Related]
20. Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat.
Desole MS; Esposito G; Fresu L; Migheli R; Enrico P; Miele M; De Natale G; Miele E
Neurosci Lett; 1993 Oct; 161(2):121-3. PubMed ID: 7903798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
